COG4-Congenital Disorder of Glycosylation

1. Disease Information

Overview. COG4-CDG(ar) is an ultra-rare autosomal recessive congenital disorder of glycosylation caused by biallelic deleterious variants in COG4, which encodes subunit 4 of the conserved oligomeric Golgi (COG) complex, a hetero-octameric vesicle-tethering complex organized in lobe A (COG1–4) and lobe B (COG5–8). Loss of COG4 destabilizes the complex and impairs retrograde intra-Golgi trafficking of glycosylation enzymes, producing combined N- and O-glycosylation defects (a CDG type II biochemical signature). It is a progressive neurometabolic disorder: "a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation" (PMID 42202558). It was first defined as CDG-IIj by Reynders et al. 2009 (PMID 19494034), which reported the first COG4-deficient patient and stated: "According to the current CDG nomenclature, this newly identified deficiency is designated CDG-IIj."

Key identifiers. - OMIM: #613489 (Congenital disorder of glycosylation, type IIj, COG4-CDG). Gene COG4 OMIM 606976. - Saul-Wilson syndrome (same gene, distinct entity): OMIM #618150. - Orphanet: ORPHA:263487 (COG-CDG group / COG4-CDG); Saul-Wilson syndrome ORPHA:3150. - ICD-10: E77.8 (other disorders of glycoprotein metabolism); ICD-11: 5C51.3 (congenital disorders of glycosylation). - MeSH: Congenital Disorders of Glycosylation (D018981). - MONDO: MONDO:0013281 (COG4-congenital disorder of glycosylation / CDG type IIj) — verified via EBI OLS4; Saul-Wilson syndrome MONDO:0019407 ("microcephalic osteodysplastic dysplasia, Saul-Wilson type") — verified via EBI OLS4. - HGNC: COG4* HGNC:2404; Ensembl ENSG00000103051; UniProt Q9H9E3; NCBI Gene 25839.

Synonyms / alternative names. COG4-CDG; CDG-IIj; CDG2J; Congenital disorder of glycosylation type IIj; Conserved oligomeric Golgi complex subunit 4 deficiency. (SWS synonyms: Saul-Wilson syndrome; microcephalic primordial dwarfism, Saul-Wilson type.)

Data provenance. Disease-level and individual case-report literature (OMIM, Orphanet, PubMed case reports/series). No EHR-derived cohort data were used.

2. Etiology

Primary causal factor — genetic. COG4-CDG(ar) is monogenic and autosomal recessive: "caused by biallelic deleterious variants in COG4, which encodes a component of the conserved oligomeric Golgi complex lobe A" (PMID 42202558). There is no environmental or infectious cause; the disease is congenital and constitutional.

Genetic risk factors. - Causal variants (biallelic): missense (e.g., p.Arg729Trp), nonsense (p.Glu233), missense p.Leu773Arg, splice-site founder allele c.1647+5G>A, and a contiguous submicroscopic deletion (Section 4). - Consanguinity / founder effect: homozygous variants arise in consanguineous or founder populations; an Italian founder haplotype (~3.36 cM) carries c.1647+5G>A (PMID 42202558). - Modifier genes: not formally established. Because the phenotype depends on residual* COG-complex function, the specific allele combination (hypomorphic vs null) is the dominant severity determinant; other COG subunits are functionally interdependent (loss of COG4 secondarily reduces COG2/COG3 and other lobe A subunits — PMID 24784932; PMID 19494034).

Environmental risk / protective factors. None identified. There are no known environmental risk factors, lifestyle factors, protective alleles, or gene–environment interactions for this monogenic disorder. (Nutritional management may modify outcome — Section 12 — but does not alter causation.)

3. Phenotypes

COG4-CDG(ar) is a multisystem disorder dominated by neurological involvement. Because only ~6–10 patients are reported, frequencies are qualitative/approximate. Phenotype types below are annotated as clinical signs (S), physical manifestations (P), or laboratory abnormalities (L).

Key supporting quotes. COG4-CDG(ar) presents with "severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections" (PMID 42202558). The COG2 report (a phenotypic sibling within COG-CDG) illustrates the shared neurometabolic pattern: "severe acquired microcephaly, psychomotor retardation, seizures, liver dysfunction, hypocupremia, and hypoceruloplasminemia" (PMID 24784932). Episodic fever is "a phenotypic feature… not seen in any other glycosylation disorder, among which episodic fever, likely reflecting underappreciated other cellular functions of the COG complex" (PMID 31804708).

Quality-of-life impact. Severe: profound psychomotor disability, epilepsy, and feeding/liver problems require lifelong multidisciplinary care and severely limit daily functioning; early mortality is common (Section 11). Formal EQ-5D/PROMIS data are not available for this ultra-rare disorder.

Saul-Wilson syndrome phenotype (distinct; for differential). Microcephalic primordial dwarfism (HP:0011451/HP:0000252), spondyloepimetaphyseal dysplasia (HP:0002656), bilateral cataract (HP:0000519), talipes equinovarus (HP:0001762), brachydactyly (HP:0001156), sensorineural hearing loss (HP:0000407), progeroid appearance (HP:0007495), characteristic facial and radiographic features, and cranio-cervical/spinal stenosis (PMID 30290151; 32652690; 35455576). Intellect is typically preserved-to-mildly affected — a major clinical contrast with COG4-CDG(ar).

4. Genetic / Molecular Information

Causal gene. COG4 (HGNC:2404; OMIM *606976; chr16q22.1; UniProt Q9H9E3). Encodes a CATCHR-fold subunit of COG lobe A.

Pathogenic variants — COG4-CDG(ar) (biallelic, germline): - c.2185C>T, p.Arg729Trp (R729W) — missense, first reported (with a submicroscopic deletion in trans), destabilizes lobe A subunits; occupies "a key position at the center of a salt bridge network, thereby stabilizing Cog4's small C-terminal domain" (PMID 19651599; clinical PMID 19494034). - p.Glu233* (E233X) — de novo nonsense; p.Leu773Arg (L773R) — missense; compound heterozygous; "COG4 protein expression was dramatically reduced" (PMID 21185756). - c.1647+5G>A — splice-site founder variant → exon 12 skipping → frameshift/premature termination codon; homozygous in Italian families (PMID 42202558). - Submicroscopic/contiguous deletion at the COG4 locus (structural; PMID 19494034).

Variant classification. Reported disease alleles are Pathogenic/Likely Pathogenic per ACMG/AMP (segregation, functional trafficking/glycosylation assays, absence/rarity in gnomAD). Some are initially reported as VUS then reclassified after functional study (e.g., PMID 34022244).

Variant types: missense, nonsense, splice-site, and structural deletion. Allele frequency: disease alleles are absent or ultra-rare in gnomAD; carrier frequency is not established (ultra-rare). Origin: germline (no somatic/cancer role). Functional consequence: loss of function / hypomorphic — reduced COG4 and secondary destabilization of the complex.

Saul-Wilson variant (dominant): c.1546G>A, p.Gly516Arg — recurrent, de novo, heterozygous; gain-of-function/neomorphic (mRNA and protein not decreased); "All affected subjects harbored heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid substitution (p.Gly516Arg)" (PMID 30290151).

Genotype–phenotype / intolerance. Lobe A genes (incl. COG4) are "less tolerant to genetic variation than COG lobe B genes"; "nearly all… lobe B COG-CDG had bi-allelic truncating mutations, as compared with only one of the six patients with lobe A COG-CDG… bi-allelic truncating mutations in COG lobe A genes might be non-viable" (PMID 28848061). Implication: complete COG4 null is likely embryonic-lethal; viable COG4-CDG(ar) patients retain residual function.

Modifier genes / epigenetics / chromosomal abnormalities. No established modifier genes or disease-specific epigenetic changes. No recurrent large chromosomal abnormalities beyond the reported private contiguous deletion.

Ontology/gene annotations. HGNC:2404; GO:0017119 (Golgi transport complex); GO:0006891 (intra-Golgi vesicle-mediated transport); GO:0007030 (Golgi organization).

5. Environmental Information

Not applicable. COG4-CDG(ar) is a constitutional monogenic disorder with no environmental factors, lifestyle factors, or infectious agents in its causation. Of note, a cellular observation links COG deficiency to infection biology in the opposite direction — COG subunits act as host entry factors for some viruses (e.g., bovine herpesvirus, via HSPG/N-glycosylation; PMID 38400072) — but this is not relevant to human disease etiology. Recurrent infections in patients are a consequence (impaired IgG glycosylation/immunity), not a cause.

6. Mechanism / Pathophysiology

Ordered causal chain — COG4-CDG(ar) (recessive, loss of function)

1. Biallelic hypomorphic/LoF COG4 variants reduce COG4 protein → destabilize the COG complex (secondary loss of COG2/COG3 and other lobe A subunits). (Demonstrated: PMID 19494034; 24784932.)
2. Destabilized COG impairs tethering of retrograde intra-Golgi (CCD) vesicles → non-tethered vesicle accumulation and disrupted Golgi/endosome morphology. (Demonstrated in cells: PMID 32730773; 31334232.)
3. Impaired tethering results in mislocalization of Golgi glycosyltransferases/glycosidases and defective Golgi SNARE-complex assembly (STX5/GS28/GS15). (Demonstrated: PMID 23865579; 37340984.)
4. Enzyme mislocalization leads to under-galactosylation and under-sialylation of N- and O-glycans (CDG type II biochemistry). (Demonstrated: PMID 42202558; 21185756.)
5. Hypoglycosylation of many glycoproteins (incl. IgG, clotting factors, hepatic and neural glycoproteins) results in multisystem dysfunction → developmental disability, epilepsy, coagulopathy, hepatopathy, recurrent infection. (Human clinical, inferred protein-by-protein: PMID 42202558.)
6. Branch — autophagy/innate function: COG complex also supports autophagy; its disruption may cause episodic fever/inflammatory features independent of glycosylation. (Inferred: PMID 31804708.)

Ordered causal chain — Saul-Wilson syndrome (dominant, gain of function; parallel branch)

1. Heterozygous p.G516R (COG4 protein/mRNA preserved) alters Golgi trafficking kinetics → delayed anterograde ER→Golgi and accelerated retrograde Golgi→ER recycling. (Demonstrated: PMID 30290151.)
2. Altered steady state reduces Golgi volume and collapses Golgi stacks. (Demonstrated: PMID 30290151.)
3. This selectively disrupts proteoglycan glycosylation/secretion — altered decorin glycosylation, glypican accumulation, reduced chondroitin-sulfate deposition — while sparing bulk N-/O-glycosylation. (Demonstrated: PMID 30290151; 34595172; 42039558.)
4. Impaired proteoglycan/ECM biology disrupts chondrocyte elongation/intercalation and chondrogenic commitment → spondyloepimetaphyseal dysplasia and primordial dwarfism. (Model + patient organoids: PMID 42039558.)

Mechanistic detail (checklist coverage)

• Molecular pathways: intra-Golgi retrograde vesicle tethering; SNARE-mediated membrane fusion; secretory pathway; glycosaminoglycan/proteoglycan biosynthesis; growth-factor signaling via HSPGs (glypicans) in SWS.
• Cellular processes: vesicle tethering/fusion (GO:0006906, GO:0048280), Golgi organization (GO:0007030), retrograde vesicle transport (GO:0006891, GO:0000301), protein glycosylation (GO:0006486), autophagy (GO:0006914), endo-lysosomal homeostasis (enlarged acidic endo-lysosomal structures; PMID 31334232).
• Protein dysfunction: loss of function/complex destabilization (recessive) vs neomorphic kinetic alteration (SWS). Cog4 C-terminal salt-bridge network is structurally critical (PMID 19651599).
• Immune involvement: recurrent infections; abnormal IgG N-glycosylation (PMID 42202558); possible autophagy-linked episodic fever (PMID 31804708).
• Tissue damage: progressive brain atrophy (neurodegeneration secondary to hypoglycosylation); hepatic dysfunction.
• Biochemical abnormalities: combined N-/O-glycan under-sialylation and under-galactosylation; occasional hypocupremia/hypoceruloplasminemia in the COG-CDG group.
• Molecular profiling: SWS time-course chondrogenic RNA-seq shows reduced skeletal-development, ECM, ossification, and GAG-metabolism gene networks; CODEX/GLYPH spatial multi-omics show altered glycosylation and reduced CS-proteoglycans (PMID 42039558). Proteomics of engineered COG4 cell lines (PMID 34603392).
• GO/CL suggestions: biological process GO:0006891, GO:0007030, GO:0006486; cell types CL:0000138 chondrocyte (SWS), CL:0000540 neuron and CL:0000127 astrocyte (CDG), CL:0000182 hepatocyte, CL:0000091 Kupffer cell.

7. Anatomical Structures Affected

Organ level (COG4-CDG(ar)). - Primary: brain/central nervous system (UBERON:0000955) — microcephaly, cerebral & cerebellar (UBERON:0002037) atrophy; liver (UBERON:0002107). - Secondary/systems: hematologic (coagulopathy), immune (recurrent infections), gastrointestinal (feeding difficulty), sometimes skeletal/connective tissue. Body systems: nervous, hepatobiliary/digestive, hematologic, immune.

Saul-Wilson (distinct): skeleton (UBERON:0002481 bone tissue; vertebral column UBERON:0001130; epiphysis/metaphysis of long bones), eye lens (UBERON:0000965; cataract), inner ear (hearing loss).

Tissue/cell level. Nervous tissue (neurons, glia); hepatic epithelium (hepatocytes CL:0000182); connective tissue/cartilage chondrocytes (CL:0000138, prominent in SWS); B-cell/plasma-cell products (IgG glycosylation).

Subcellular level (central to pathogenesis). Golgi apparatus (GO:0005794) — the primary organelle; Golgi transport/COG complex (GO:0017119); ER–Golgi intermediate compartment; endosome/lysosome (enlarged endo-lysosomal structures, GO:0005764/GO:0005768).

Localization/lateralization. Bilateral and symmetric where applicable (bilateral cataracts, symmetric brain atrophy). No lateralization.

8. Temporal Development

• Onset: congenital/neonatal to early infantile. Microcephaly is characteristically post-natal (acquired), i.e., normal or near-normal head size at birth with progressive deceleration (PMID 42202558; cf. PMID 24784932 "severe acquired microcephaly").
• Onset pattern: chronic with early presentation; feeding problems, hypotonia, and seizures in infancy.
• Progression: progressive neurodegenerative course ("progressive course leading to severe global disability," PMID 42202558) with brain atrophy; multisystem complications accrue.
• Course pattern: chronic-progressive; episodic fever superimposes an episodic element in COG-CDG (PMID 31804708).
• Duration: lifelong; frequently shortened by early mortality (perinatal/infantile CDG-II cases have the highest mortality — PMID 23401092).
• Remission: none spontaneous; management is supportive.
• Critical periods: infancy/early childhood (neurodevelopmental window) is the period of greatest vulnerability and the target for early supportive intervention.

9. Inheritance and Population

Epidemiology. Ultra-rare. COG4-CDG(ar) has been "described in six individuals to date" (PMID 42202558), with a few additional cases (~<10 total). Precise prevalence/incidence are unknown (Orphanet: prevalence <1/1,000,000). The broader COG-CDG group comprises "over a hundred individuals with 31 different COG mutations" across all subunits (PMID 34603392).

Inheritance (COG4-CDG(ar)): Autosomal recessive, biallelic. Penetrance appears complete in biallelic carriers; expressivity is variable (allele-dependent). No genetic anticipation. Germline mosaicism not reported for the recessive form. - Founder effect: Italian founder haplotype for c.1647+5G>A (PMID 42202558). - Consanguinity: contributes (homozygous variants in related families). - Carrier frequency: not established; expected extremely low.

Inheritance (Saul-Wilson): Autosomal dominant, essentially all cases de novo p.G516R; hence negligible recurrence risk for unaffected parents but germline mosaicism is theoretically possible. Complete penetrance for the specific allele.

Population demographics. Reported patients span multiple ancestries (European incl. Italian/Portuguese, South Asian/Indian-origin, others). No strong sex bias expected for an autosomal disorder (male:female ≈ 1:1). Age distribution skews pediatric due to early onset and reduced survival.

10. Diagnostics

First-line biochemical screening. - Serum transferrin isoelectric focusing (IEF)/CZE/HPLC → typically a CDG type II pattern (increased di-/tri-sialotransferrin; loss of terminal sialic acid ± galactose). LOINC-type analyte: transferrin glycoform profile. - Important pitfall: COG4-CDG can show normal transferrin despite Golgi disruption — "two COG4-CDG, with normal transferrin screening analyses" (PMID 34022244). A normal transferrin screen does not exclude COG4-CDG.

Second-line glyco-analysis (when transferrin is normal or to characterize type II). - Apolipoprotein C-III (apoC-III) IEF/2-DE for mucin-type O-glycosylation ("apoC-III" hypoglycosylation shift) — rescues otherwise-missed cases (PMID 34022244). - Serum N-glycome by MALDI-TOF MS (deficient galactosylation/sialylation), haptoglobin 2-DE, and IgG N-glycan analysis (PMID 42202558).

Cellular/functional assays (research/confirmatory). Fibroblast brefeldin-A–induced retrograde transport delay (hallmark of COG deficiency; PMID 21185756; 19690088); Western blot showing reduced COG4 ± other subunits.

Genetic testing (definitive). Whole-exome or whole-genome sequencing and CDG gene panels identify biallelic COG4 variants; some cases are solved only by WES when transferrin is normal (PMID 33340551; 34022244). RNA/whole-transcriptome sequencing confirms splice effects (exon 12 skipping; PMID 42202558). SNP-array for the contiguous deletion/founder haplotype. Recommended approach: transferrin screen → (if suggestive or high suspicion despite normal screen) apoC-III/N-glycome → WES/panel → RNA studies for splice/VUS resolution.

Imaging & other. Brain MRI: cerebral/cerebellar atrophy, microcephaly. EEG for seizures. Liver panel/coagulation studies. SWS additionally requires skeletal survey (spondyloepimetaphyseal dysplasia) and ophthalmologic (cataract) evaluation.

Clinical criteria / differential. No formal consensus criteria; diagnosis is molecular. Differential diagnosis: other COG-CDGs (COG1,2,3,5,6,7,8), PMM2-CDG and other CDG-I/II, ATP6V0A2-CDG (cutis laxa, also Golgi-homeostasis with normal transferrin), mitochondrial encephalopathies, and (for SWS) other primordial dwarfisms/spondyloepimetaphyseal dysplasias.

Screening. Not part of routine newborn screening. Cascade/carrier testing and prenatal testing are possible once familial variants are known.

11. Outcome / Prognosis

Survival/mortality. Guarded. COG4-CDG(ar) follows "a progressive course leading to severe global disability" (PMID 42202558). Severe neonatal/infantile CDG-II presentations carry the highest mortality: "Cases presenting in the neonatal period had the highest mortality rate" (PMID 23401092). No formal 5-/10-year survival statistics exist for this ultra-rare disorder; life expectancy is often reduced (early childhood death in severe cases), though milder survivors reaching adulthood are reported (adult siblings, PMID 34022244).

Morbidity/function. Profound: severe intellectual disability, refractory epilepsy, motor impairment, feeding/liver problems, bleeding risk, and infection susceptibility → lifelong dependency. ICF-level: severe global functional impairment.

Complications. Status epilepticus, hepatic failure/coagulopathy, bleeding, recurrent/serious infections, failure to thrive. (SWS complications: cranio-cervical/spinal stenosis with myelopathy risk — PMID 35455576.)

Prognostic factors. Allele severity (residual COG function), age at onset (neonatal = worse), degree of hepatic/coagulation involvement, seizure control. Prognostic biomarkers: severity of transferrin/N-glycan hypoglycosylation broadly tracks complex disruption but is not a validated individual predictor.

12. Treatment

No curative or disease-specific therapy exists for COG4-CDG(ar). Management is supportive and multidisciplinary, guided by general CDG principles (PMID 31534212; 35562242).

• Symptomatic pharmacotherapy: anti-seizure medications for epilepsy (NCIT: Anticonvulsant Agent); management of coagulopathy (fresh frozen plasma/factor support perioperatively); treatment of infections; hepatoprotective/supportive care. Pharmacogenomics: none specific.
• Nutrition: individualized nutritional support for failure to thrive; note that specific monosaccharide therapies effective in other CDGs (e.g., mannose in MPI-CDG, galactose in some, manganese in TMEM165/SLC39A8) have no proven benefit in COG4-CDG; nutritional management is supportive (PMID 35562242; 31534212). Avoid overly aggressive nutritional interventions.
• Rehabilitation/supportive: physical, occupational, speech therapy; developmental support; feeding support (NG/gastrostomy as needed); hearing/vision management.
• Surgical/interventional: as dictated by complications (e.g., SWS cranio-cervical decompression; PMID 35455576).
• Advanced/experimental therapeutics: no approved gene, cell, or RNA therapy for COG4-CDG. General CDG therapeutic pipelines (activated sugars, chaperones, gene therapy, transplantation) are reviewed but not established for COG-CDG (PMID 31534212). No registered COG4-CDG–specific clinical trials identified.
• Palliative care: appropriate trigger-point referral for severe multisystem IMDs, including CDG (PMID 41466310).
• SWS note: growth hormone supplementation does not improve height in Saul-Wilson syndrome (PMID 32652690).

NCIT term suggestions: Supportive Care (C15277); Anticonvulsant Agent (C264); Physical Therapy (C15451); Nutritional Support (C15845); Genetic Counseling (C15417).

13. Prevention

• Primary prevention: not possible for this constitutional genetic disorder. Genetic counseling is central: 25% recurrence risk for future pregnancies of carrier couples (AR); for SWS, low recurrence (de novo) but germline mosaicism caveat.
• Reproductive options: carrier testing of relatives, prenatal diagnosis, and preimplantation genetic testing (PGT-M) once familial variants are known.
• Secondary prevention: early diagnosis (including recognizing that transferrin may be normal) to enable early supportive intervention; early cardiac, hepatic, coagulation, seizure, hearing, and developmental assessments.
• Tertiary prevention: proactive management of coagulopathy before procedures, infection prophylaxis/prompt treatment, seizure control, nutritional optimization to prevent complications.
• Immunization / public-health / environmental measures: not applicable to causation; standard vaccinations advisable given infection susceptibility.

14. Other Species / Natural Disease

• Taxonomy / orthologs: COG4 is evolutionarily conserved across metazoa and fungi. Orthologs/homologs: mouse Cog4 (NCBI Gene 102831), zebrafish cog4, Drosophila melanogaster (Cog homologs), Caenorhabditis elegans (cogc-4), and Saccharomyces cerevisiae COG complex (Cod/Sec/Cog genes). The COG tethering mechanism and CATCHR fold are ancient and conserved (PMID 25331899; 19651599).
• Natural disease in other species: No naturally occurring COG4 disease is documented in companion animals or wildlife (no OMIA entry known). Veterinary relevance is limited to experimental models.
• Comparative biology: COG function is conserved; yeast/CHO COG mutants recapitulate glycosylation/trafficking defects, underpinning mechanistic understanding (e.g., CHO α-dystroglycan mucin-type O-glycosylation defects — PMID 30049793).
• Transmission / zoonosis: not applicable (non-infectious).

15. Model Organisms

In vitro / cellular models. - CRISPR/Cas9 isogenic RPE1 and HEK293T lines expressing WT vs mutant COG4 (G516R, R729W) under the endogenous promoter; COG4-G516R cells show increased HPA-647 lectin binding, R729W distinct defects (PMID 34603392) — a purpose-built COG-CDG-II cellular platform. - HEK293T COG1–8 knockouts: reduced glycosaminoglycan/proteoglycan modification (PMID 34053170). - SW1353 chondrosarcoma cells (G516R): reduced ECM secretion (PMID 42039558). - Patient fibroblasts: BFA-retrograde-transport delay; reduced COG4/lobe A subunits (PMID 19494034; 21185756). - Patient iPSC-derived cartilage organoids (SWS): recapitulate defective chondrogenesis, reduced CS-proteoglycan deposition, altered chondrogenic trajectory (PMID 42039558).

Whole-organism models. - Zebrafish (Danio rerio): embryos expressing COG4 G516R show defective chondrocyte elongation/intercalation and glypican accumulation — recapitulate SWS skeletal mechanism (PMID 34595172; 42039558). - C. elegans: knock-in of the equivalent Saul-Wilson allele did not show obvious Golgi defects — a limitation illustrating tissue/context dependence (PMID 33688625). - Drosophila: COG7 (and related COG) models exist for the COG-CDG group (PMID 28883096), useful for conserved trafficking/glycosylation biology. - Mouse: no widely reported published Cog4 CDG-IIj mouse model; complete knockout expected to be lethal (consistent with lobe-A intolerance, PMID 28848061).

Model characteristics. Cellular and zebrafish/organoid models faithfully reproduce trafficking and proteoglycan/ECM phenotypes (esp. for SWS); the neurodevelopmental/hepatic phenotype of recessive COG4-CDG is not fully captured by any single model. Limitations: invertebrate models may lack the human skeletal/neural phenotype (C. elegans negative result); patient fibroblasts do not represent all affected organs (PMID 34603392).

Resources: ZFIN (zebrafish), WormBase (C. elegans), FlyBase (Drosophila), Cellosaurus/ATCC (cell lines), Alliance of Genome Resources (orthology).

Summary of Supported / Refuted Hypotheses

Supported: - COG4 causes two distinct disorders (recessive COG4-CDG/CDG-IIj and dominant Saul-Wilson syndrome). ✔ (PMID 42202558; 30290151) - COG4-CDG(ar) is a progressive neurometabolic multisystem disorder with combined N-/O-glycosylation defects from impaired Golgi retrograde tethering. ✔ (PMID 42202558; 32730773; 21185756) - Saul-Wilson p.G516R is a gain-of-function allele (accelerated retrograde trafficking, selective proteoglycan defect, preserved bulk glycosylation). ✔ (PMID 30290151; 34595172; 42039558) - Biallelic truncating COG4 alleles are likely non-viable; viable patients retain residual function. ✔ (PMID 28848061) - Transferrin IEF can be falsely normal in COG4-CDG; apoC-III/N-glycome needed. ✔ (PMID 34022244)

Refuted / negative findings: - Growth hormone improves height in SWS — refuted (PMID 32652690). - A simple C. elegans knock-in reproduces the Golgi defect — not supported (PMID 33688625). - Environmental/infectious causation — none (monogenic).

Limitations and Future Directions

• Ultra-rare (<10 recessive cases): frequencies are qualitative; no formal prevalence, survival, or QoL data.
• No mouse model / no curative therapy; natural-history and registry data are needed.
• Mechanistic gaps: how hypoglycosylation drives progressive brain atrophy; the autophagy/episodic-fever link; genotype–phenotype rules for specific allele combinations.
• Future work: targeted glyco-diagnostics adoption (recognizing normal-transferrin cases), functional reclassification of VUS, and development of trafficking-modulating or gene-based therapies.

Evidence types: human clinical case reports/series (PMID 42202558, 30290151, 21185756, 19494034, 34022244, 24784932, 33340551, 32652690, 35455576, 23401092); in vitro/cellular (34603392, 34053170, 23865579, 37340984, 31334232, 19651599, 30049793); model organism (42039558, 34595172, 33688625, 28883096); computational/structural (19651599, 39809522); reviews/hypotheses (32730773, 28848061, 31804708, 31534212, 35562242).

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

• PMID:31804708: "a phenotypic feature… not seen in any other glycosylation disorder, among which episodic fever, likely reflecting underappreciated other cellular functions of the COG complex"
• closest text in source: "Moreover, it captured features not seen in any other glycosylation disorder, among which episodic fever, likely reflecting underappreciated other cellular functions of the COG complex"
• PMID:19494034: "a key position at the center of a salt bridge network, thereby stabilizing Cog4's small C-terminal domain"
• closest text in source: "More recently a two-phase membrane system was proposed in which small soluble cargo distributes equally across the stack and membrane proteins prefer certain cisternae only based on, for instance, the local lipid composition and length of the transmembrane domain (10)"
• PMID:28848061: "nearly all… lobe B COG-CDG had bi-allelic truncating mutations, as compared with only one of the six patients with lobe A COG-CDG… bi-allelic truncating mutations in COG lobe A genes might be non-viable"
• closest text in source: "Second, nearly all of the 27 patients with lobe B COG-CDG had bi-allelic truncating mutations, as compared with only one of the six patients with lobe A COG-CDG"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0006486 (obsolete protein glycosylation) (2 mentions) - replaced by GO:0009101

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• MONDO:0013281 (1 mention) - the report calls it "COG4-congenital disorder of glycosylation / CDG type IIj"; MONDO calls it COG4-congenital disorder of glycosylation, and lists "congenital disorder of glycosylation type IIj" among its other names
• GO:0017119 (2 mentions) - the report calls it "Golgi transport complex"; GO calls it COG complex, and lists "Golgi transport complex" among its other names
• UBERON:0000955 (1 mention) - the report calls it "Primary: brain/central nervous system"; UBERON calls it brain**, and lists "suprasegmental levels of nervous system" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

47 of 51 terms resolved to a current term; the rest could not be looked up either way.